{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:50:45Z","timestamp":1793051445992,"version":"4.5.0"},"reference-count":118,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100004564","name":"Ministry of Education, Science and Technological Development of the Republic of Serbia","doi-asserted-by":"publisher","award":["451-03-9\/2021-14\/200113"],"award-info":[{"award-number":["451-03-9\/2021-14\/200113"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Hypertensive left ventricular hypertrophy (HTN LVH) is a key risk factor\nfor atrial fibrillation (AF).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To evaluate the possible role of beta-blockers (BBs) in addition to a renin-angiotensinaldosterone\nsystem (RAAS) blocker in AF prevention in patients with HTN LVH.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We performed a PubMed, Elsevier, SAGE, Oxford, and Google Scholar search with the\nsearch items \u2018beta blocker hypertension left ventricular hypertrophy patient\u2019 from 2013-2023. In the\nend, a \u2018snowball search\u2019, based on the references of relevant papers as well as from papers that cited\nthem was performed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>HTN LVH is a risk factor for AF. In turn, AF substantially complicates HTN LVH and contributes\nto the genesis of heart failure (HF) with preserved ejection fraction (HFpEF). The prognosis\nof HFpEF is comparable with that of HF with reduced EF (HFrEF), and, regardless of the type, HF is\nassociated with five-year mortality of 50-75%. The antiarrhythmic properties of BBs are wellrecognized,\nand BBs as a class of drugs are - in general - recommended to decrease the incidence of\nAF in HTN.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>BBs are recommended (as a class) for AF prevention in several contemporary guidelines\nfor HTN. LVH regression in HTN - used as a single criterion for the choice of antihypertensive medication\n- does not capture this protective effect. Consequently, it is worth studying how meaningful\nthis antiarrhythmic action (to prevent AF) of BBs is in patients with HTN LVH in addition to a\nRAAS blocker.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115701611264647231110101700","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T09:30:52Z","timestamp":1701336652000},"page":"19-27","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Beta-blockers in Hypertensive Left Ventricular Hypertrophy and Atrial\nFibrillation Prevention"],"prefix":"10.2174","volume":"22","author":[{"given":"Goran","family":"Kora\u0107evi\u0107","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Diseases, University Clinical Center Ni\u0161, Serbia"},{"name":"Faculty of Medicine, Ni\u0161 University,\nSerbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sladjana","family":"Mi\u0107i\u0107","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Clinical Center Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milovan","family":"Stojanovi\u0107","sequence":"additional","affiliation":[{"name":"Institute for Treatment and Rehabilitation\nNi\u0161ka Banja, Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Zdravkovic","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Hospital Medical Center Be\u017eanijska kosa and Faculty\nof Medicine, University of Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Simi\u0107","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, University Clinical Center Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomislav","family":"Kosti\u0107","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, University Clinical Center Ni\u0161, Serbia"},{"name":"Faculty of Medicine, Ni\u0161 University, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Atanaskovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, University Clinical Center Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru\u017eica","family":"Jankovi\u0107-Toma\u0161evi\u0107","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, University Clinical Center Ni\u0161, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.3390\/jcm11185377","volume":"11","author":"Mancusi C.","year":"2022","unstructured":"Mancusi C.; Lembo M.; Manzi M.V.; Basile C.; Fucile I.; Morisco C.; From structural to functional hypertension mediated target organ damage\u2014a long way to heart failure with preserved ejection fraction. J Clin Med  2022,11(18),5377","journal-title":"J Clin Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1159\/000500782","volume":"44","author":"Wang T.","year":"2019","unstructured":"Wang T.; Zhong H.; Lian G.; Low-grade albuminuria is associated with left ventricular hypertrophy and diastolic dysfunction in patients with hypertension. Kidney Blood Press Res  2019,44(4),590-603","journal-title":"Kidney Blood Press Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ijcard.2017.06.123","volume":"249","author":"Kim Y.","year":"2017","unstructured":"Kim Y.; Cho J.S.; Cho W.; Retinopathy and left ventricular hypertrophy in patients with chronic kidney disease: interrelationship and impact on clinical outcomes. Int J Cardiol  2017,249,372-376","journal-title":"Int J Cardiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.3390\/jcm11133885","volume":"11","author":"Ovchinnikov A.","year":"2022","unstructured":"Ovchinnikov A.; Belyavskiy E.; Potekhina A.; Ageev F.; Asymptomatic left ventricular hypertrophy is a potent risk factor for the development of hfpef but not hfref: Results of a retrospective cohort study. J Clin Med  2022,11(13),3885","journal-title":"J Clin Med"},{"key":"ref=5","author":"Tackling G.","year":"2022","unstructured":"Tackling G.; Borhade M.B.; Hypertensive heart disease. StatPearls  Available from:  https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539800\/ Updated 2022 Jun 27 Jan.2022","journal-title":"StatPearls"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.25122\/jml-2022-0214","volume":"15","author":"Al Alwany A.A.","year":"2022","unstructured":"Al Alwany A.A.; Arrhythmia related to hypertensive left ventricular hypertrophy in Iraqi patients: Frequency and outcome. J Med Life  2022,15(9),1115-1118","journal-title":"J Med Life"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1159\/000526792","volume":"31","author":"Koracevic G.","year":"2022","unstructured":"Koracevic G.; Perisic Z.; Stanojkovic M.; A discrepancy: Calcium channel blockers are effective for the treatment of hypertensive left ventricular hypertrophy but not as effective for prevention of heart failure. Med Princ Pract  2022,31(5),454-462","journal-title":"Med Princ Pract"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/jch.13795","volume":"22","author":"Zhang H.","year":"2020","unstructured":"Zhang H.; Hu L.; Wei X.; Prognostic value of left ventricular hypertrophy in hypertensive patients: A meta-analysis of electrocardiographic studies. J Clin Hypertens  2020,22(2),254-260","journal-title":"J Clin Hypertens"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.37349\/emed.2022.00080","volume":"3","author":"Bang C.N.","year":"2022","unstructured":"Bang C.N.; Greve A.M.; K&#xF8;ber L.; Incident atrial fibrillation and heart failure in treated hypertensive patients with left ventricular hypertrophy. The life study. Exploration of Medicine  2022,3,139-148","journal-title":"Exploration of Medicine"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e187419242212020","DOI":"10.2174\/18741924-v16-e221202-2022-8","volume":"16","author":"Noori A.A.","year":"2022","unstructured":"Noori A.A.; Barzani M.A.; Predictors of impaired left ventricular global longitudinal strain in patients with essential hypertension and preserved ejection fraction. Open Cardiovasc Med J  2022,16(1),e187419242212020","journal-title":"Open Cardiovasc Med J"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41371-020-00427-x","volume":"35","author":"Nadar S.K.","year":"2021","unstructured":"Nadar S.K.; Lip G.Y.H.; The heart in hypertension. J Hum Hypertens  2021,35(5),383-386","journal-title":"J Hum Hypertens"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.amjcard.2018.04.053","volume":"122","author":"Erk&#xFC;ner &#xD6;.","year":"2018","unstructured":"Erk&#xFC;ner &#xD6;.; Dudink E.A.M.P.; Nieuwlaat R.; Effect of systemic hypertension with versus without left ventricular hypertrophy on the progression of atrial fibrillation (from the euro heart survey). Am J Cardiol  2018,122(4),578-583","journal-title":"Am J Cardiol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCEP.108.795351","volume":"1","author":"Okin P.M.","year":"2008","unstructured":"Okin P.M.; Wachtell K.; Kjeldsen S.E.; Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: The LIFE study. Circ Arrhythm Electrophysiol  2008,1(5),337-343","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/ehjcvp\/pvx019","volume":"3","author":"Lip G.Y.H.","year":"2017","unstructured":"Lip G.Y.H.; Coca A.; Kahan T.; Hypertension and cardiac arrhythmias: executive summary of a consensus document from the european heart rhythm association (ehra) and esc council on hypertension, endorsed by the heart rhythm society (hrs), asia-pacific heart rhythm society (aphrs) and sociedad latinoamericana de estimulaci&#xF3;n card&#xED;aca y electrofisiolog&#xED;a (SOLEACE). Eur Heart J Cardiovasc Pharmacother  2017,3(4),235-250","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2174\/1570161120666220819095215","volume":"20","author":"Kora\u0107evi\u0107 G.","year":"2022","unstructured":"Kora\u0107evi\u0107 G.; Stojkovi\u0107 M.; Stojanovi\u0107 M.; Less known but\nclinically relevant comorbidities of atrial fibrillation: A narrative\nreview. Curr Vasc Pharmacol  2022,20(5),429-38","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e026240","DOI":"10.1161\/JAHA.122.026240","volume":"12","author":"Kanazawa S.","year":"2023","unstructured":"Kanazawa S.; Kaneko H.; Yano Y.; Sex differences in the association between hypertension and incident atrial fibrillation. J Am Heart Assoc  2023,12(5),e026240","journal-title":"J Am Heart Assoc"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1186\/s12889-022-14403-2","volume":"22","author":"Li H.","year":"2022","unstructured":"Li H.; Song X.; Liang Y.; Global, regional, and national burden of disease study of atrial fibrillation\/flutter, 1990\u20132019: Results from a global burden of disease study, 2019. BMC Public Health  2022,22(1),2015","journal-title":"BMC Public Health"},{"key":"ref=18","doi-asserted-by":"publisher","DOI":"10.2174\/1570161121666230201141215","author":"Koracevic G","year":"2023","unstructured":"Koracevic G; Mi\u0107i\u0107 S; Stojanovic M; In many patients with hypertensive left ventricular hypertrophy, a beta-blocker is needed because of the prevalent myocardial ischemia. Curr Vasc Pharmacol  Epub ahead of print2023","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.amjcard.2010.07.037","volume":"106","author":"Dabrowski R.","year":"2010","unstructured":"Dabrowski R.; Borowiec A.; Smolis-Bak E.; Effect of combined spironolactone-&#x3B2;-blocker &#xB1; enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am J Cardiol  2010,106(11),1609-1614","journal-title":"Am J Cardiol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1161\/CIRCEP.112.977777","volume":"6","author":"Okin P.M.","year":"2013","unstructured":"Okin P.M.; Bang C.N.; Wachtell K.; Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. Circ Arrhythm Electrophysiol  2013,6(2),243-251","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.120.16659","volume":"77","author":"Lee S.R.","year":"2021","unstructured":"Lee S.R.; Park C.S.; Choi E.K.; Hypertension Burden and the Risk of New-Onset Atrial Fibrillation. Hypertension  2021,77(3),919-928","journal-title":"Hypertension"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"Umemura S.","year":"2019","unstructured":"Umemura S.; Arima H.; Arima S.; The Japanese society of hypertension guidelines for the management of hypertension (jsh 2019). Hypertens Res  2019,42(9),1235-1481","journal-title":"Hypertens Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijcard.2017.03.002","volume":"237","author":"Shenasa M.","year":"2017","unstructured":"Shenasa M.; Shenasa H.; Hypertension, left ventricular hypertrophy, and sudden cardiac death. Int J Cardiol  2017,237,60-63","journal-title":"Int J Cardiol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.21037\/apm-19-649","volume":"9","author":"Chen C.","year":"2020","unstructured":"Chen C.; Liu L.; Yu Y.; Association of systolic blood pressure with atrial fibrillation among treated hypertensive patients. Ann Palliat Med  2020,9(4),1752-1763","journal-title":"Ann Palliat Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.ahj.2012.02.015","volume":"163","author":"De Vos C.B.","year":"2012","unstructured":"De Vos C.B.; Breithardt G.; Camm A.J.; Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: Clinical correlates and the effect of rhythm-control therapy. Am Heart J  2012,163(5),887-893","journal-title":"Am Heart J"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"Lip G.Y.H.","year":"2010","unstructured":"Lip G.Y.H.; Nieuwlaat R.; Pisters R.; Lane D.A.; Crijns H.J.G.M.; Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest  2010,137(2),263-272","journal-title":"Chest"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"d124","DOI":"10.1136\/bmj.d124","volume":"342","author":"Olesen JB","year":"2011","unstructured":"Olesen JB; Lip GYH; Hansen ML; Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ  2011,342(jan31 1),d124","journal-title":"BMJ"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"e12419","DOI":"10.1111\/anec.12419","volume":"22","author":"Patel N.","year":"2017","unstructured":"Patel N.; O\u2019Neal W.T.; Whalen S.P.; Soliman E.Z.; Electrocardiographic left ventricular hypertrophy predicts atrial fibrillation independent of left ventricular mass. Ann Noninvasive Electrocardiol  2017,22(3),e12419","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.pcad.2018.11.002","volume":"61","author":"Stewart M.H.","year":"2018","unstructured":"Stewart M.H.; Lavie C.J.; Shah S.; Prognostic implications of left ventricular hypertrophy. Prog Cardiovasc Dis  2018,61(5-6),446-455","journal-title":"Prog Cardiovasc Dis"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/j.jacc.2014.01.066","volume":"63","author":"Chrispin J.","year":"2014","unstructured":"Chrispin J.; Jain A.; Soliman E.Z.; Association of electrocardiographic and imaging surrogates of left ventricular hypertrophy with incident atrial fibrillation: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol  2014,63(19),2007-2013","journal-title":"J Am Coll Cardiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.hrthm.2017.01.038","volume":"14","author":"Padfield G.J.","year":"2017","unstructured":"Padfield G.J.; Steinberg C.; Swampillai J.; Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the canadian registry of atrial fibrillation. Heart Rhythm  2017,14(6),801-807","journal-title":"Heart Rhythm"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/europace\/eux091","volume":"19","author":"Lip G.Y.H.","year":"2017","unstructured":"Lip G.Y.H.; Coca A.; Kahan T.; Hypertension and cardiac arrhythmias: A consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci&#xF3;n Card&#xED;aca y Electrofisiolog&#xED;a (SOLEACE). Europace  2017,19(6),891-911","journal-title":"Europace"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/jcdd9040110","volume":"9","author":"Marazzato J.","year":"2022","unstructured":"Marazzato J.; Blasi F.; Golino M.; Verdecchia P.; Angeli F.; De Ponti R.; Hypertension and Arrhythmias: A clinical overview of the pathophysiology-driven management of cardiac arrhythmias in hypertensive patients. J Cardiovasc Dev Dis  2022,9(4),110","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.26355\/eurrev_202002_20196","volume":"24","author":"Koracevic G","year":"2020","unstructured":"Koracevic G; Mi\u0107i\u0107 S; Stojanovi\u0107 M; High likelihood for atrial fibrillation in Cushing\u2019s syndrome. Eur Rev Med Pharmacol Sci  2020,24(3),1391-1397","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"6366","DOI":"10.1038\/s41598-018-24875-1","volume":"8","author":"Seko Y.","year":"2018","unstructured":"Seko Y.; Kato T.; Haruna T.; Association between atrial fibrillation, atrial enlargement, and left ventricular geometric remodeling. Sci Rep  2018,8(1),6366","journal-title":"Sci Rep"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1161\/01.HYP.0000052830.02773.E4","volume":"41","author":"Verdecchia P.","year":"2003","unstructured":"Verdecchia P.; Reboldi G.; Gattobigio R.; Atrial fibrillation in hypertension: Predictors and outcome. Hypertension  2003,41(2),218-223","journal-title":"Hypertension"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.amjcard.2015.05.060","volume":"116","author":"Proietti M.","year":"2015","unstructured":"Proietti M.; Marra A.M.; Tassone E.J.; Frequency of left ventricular hypertrophy in non-valvular atrial fibrillation. Am J Cardiol  2015,116(6),877-882","journal-title":"Am J Cardiol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12933-023-01736-4","volume":"22","author":"Choi J.","year":"2023","unstructured":"Choi J.; Lee S.R.; Choi E.K.; Accumulated hypertension burden on atrial fibrillation risk in diabetes mellitus: A nationwide population study. Cardiovasc Diabetol  2023,22(1),12","journal-title":"Cardiovasc Diabetol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/jch.14524","volume":"24","author":"Huang P.H.","year":"2022","unstructured":"Huang P.H.; Huang C.C.; Lin S.J.; Chen J.W.; Prediction of atrial fibrillation in patients with hypertension: A comprehensive comparison of office and ambulatory blood pressure measurements. J Clin Hypertens  2022,24(7),838-847","journal-title":"J Clin Hypertens"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1111\/jch.13989","volume":"22","author":"Varvarousis D.","year":"2020","unstructured":"Varvarousis D.; Kallistratos M.; Poulimenos L.; Cardiac arrhythmias in arterial hypertension. J Clin Hypertens  2020,22(8),1371-1378","journal-title":"J Clin Hypertens"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s13239-021-00527-w","volume":"12","author":"Qiu D.","year":"2021","unstructured":"Qiu D.; Peng L.; Ghista D.N.; Wong K.K.L.; Left atrial remodeling mechanisms associated with atrial fibrillation. Cardiovasc Eng Technol  2021,12(3),361-372","journal-title":"Cardiovasc Eng Technol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"862164","DOI":"10.3389\/fphys.2022.862164","volume":"13","author":"Ihara K.","year":"2022","unstructured":"Ihara K.; Sasano T.; Role of inflammation in the pathogenesis of atrial fibrillation. Front Physiol  2022,13,862164","journal-title":"Front Physiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/0002-9343(84)90430-3","volume":"77","author":"Messerli F.H.","year":"1984","unstructured":"Messerli F.H.; Ventura H.O.; Elizardi D.J.; Dunn F.G.; Frohlich E.D.; Hypertension and sudden death. Am J Med  1984,77(1),18-22","journal-title":"Am J Med"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"141B","DOI":"10.1016\/S0735-1097(85)80545-3","volume":"5","author":"Kannel W.B.","year":"1985","unstructured":"Kannel W.B.; Schatzkin A.; Sudden death: Lessons from subsets in population studies. J Am Coll Cardiol  1985,5(6)(Suppl.),141B-149B","journal-title":"J Am Coll Cardiol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJM198709243171302","volume":"317","author":"McLenachan J.M.","year":"1987","unstructured":"McLenachan J.M.; Henderson E.; Morris K.I.; Dargie H.J.; Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. N Engl J Med  1987,317(13),787-792","journal-title":"N Engl J Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"560e565","DOI":"10.1016\/0002-9149(87)90305-5","volume":"60","author":"Levy D","year":"1987","unstructured":"Levy D; Anderson KM; Savage DD; Balkus SA; Kannel WB; Castelli WP; Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. Am J Cardiol  1987,60,560e565","journal-title":"Am J Cardiol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S0735-1097(10)80135-4","volume":"17","author":"Ghali J.K.","year":"1991","unstructured":"Ghali J.K.; Kadakia S.; Cooper R.S.; Liao Y.; Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol  1991,17(6),1277-1282","journal-title":"J Am Coll Cardiol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0002-8703(92)90751-G","volume":"123","author":"Schmieder R.E.","year":"1992","unstructured":"Schmieder R.E.; Messerli F.H.; Determinants of ventricular ectopy in hypertensive cardiac hypertrophy. Am Heart J  1992,123(1),89-95","journal-title":"Am Heart J"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/eurheartj\/13.suppl_D.70","volume":"13","author":"Vester E.G.","year":"1992","unstructured":"Vester E.G.; Kuhls S.; Ochiulet-Vester J.; Vogt M.; Strauer B.E.; Electrophysiological and therapeutic implications of cardiac arrhythmias in hypertension. Eur Heart J  1992,13(Suppl. D),70-81","journal-title":"Eur Heart J"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1053\/eupc.2000.0110","volume":"2","author":"Wolk R.","year":"2000","unstructured":"Wolk R.; Arrhythmogenic mechanisms in left ventricular hypertrophy. Europace  2000,2(3),216-223","journal-title":"Europace"},{"key":"ref=51","first-page":"14","volume":"2","author":"Greenberg M.D.","year":"2000","unstructured":"Greenberg M.D.; Papademetriou V.; Narayan P.; Kokkinos P.; Nonsustained Ventricular Tachycardia as a Predictor of Cardiovascular Events in Black Men With Hypertensive Left Ventricular Hypertrophy. J Clin Hypertens  2000,2(1),14-19","journal-title":"J Clin Hypertens"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1161\/01.CIR.103.19.2346","volume":"103","author":"Sundstr&#xF6;m J.","year":"2001","unstructured":"Sundstr&#xF6;m J.; Lind L.; &#xC4;rnl&#xF6;v J.; Zethelius B.; Andr&#xE9;n B.; Lithell H.O.; Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation  2001,103(19),2346-2351","journal-title":"Circulation"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.amjcard.2014.07.015","volume":"114","author":"Chatterjee S.","year":"2014","unstructured":"Chatterjee S.; Bavishi C.; Sardar P.; Meta-analysis of left ventricular hypertrophy and sustained arrhythmias. Am J Cardiol  2014,114(7),1049-1052","journal-title":"Am J Cardiol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.jelectrocard.2014.06.002","volume":"47","author":"Rautaharju P.M.","year":"2014","unstructured":"Rautaharju P.M.; Soliman E.Z.; Electrocardiographic left ventricular hypertrophy and the risk of adverse cardiovascular events: A critical appraisal. J Electrocardiol  2014,47(5),649-654","journal-title":"J Electrocardiol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.hrthm.2014.03.023","volume":"11","author":"Narayanan K.","year":"2014","unstructured":"Narayanan K.; Reinier K.; Teodorescu C.; Electrocardiographic versus echocardiographic left ventricular hypertrophy and sudden cardiac arrest in the community. Heart Rhythm  2014,11(6),1040-1046","journal-title":"Heart Rhythm"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"e001193","DOI":"10.1161\/JAHA.114.001193","volume":"3","author":"Narayanan K.","year":"2014","unstructured":"Narayanan K.; Reinier K.; Teodorescu C.; Left ventricular diameter and risk stratification for sudden cardiac death. J Am Heart Assoc  2014,3(5),e001193","journal-title":"J Am Heart Assoc"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"ii7","DOI":"10.1093\/europace\/euv121","volume":"17 Suppl 2","author":"Narayanan K","year":"2015","unstructured":"Narayanan K; Chugh SS; The 12-lead electrocardiogram and risk\nof sudden death: current utility and future prospects. Europace  2015,17 Suppl 2(Suppl 2),ii7-ii13","journal-title":"Europace"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"e003629","DOI":"10.1161\/CIRCEP.115.003629","volume":"9","author":"Aro A.L.","year":"2016","unstructured":"Aro A.L.; Chugh S.S.; Clinical Diagnosis of Electrical Versus Anatomic Left Ventricular Hypertrophy: Prognostic and Therapeutic Implications. Circ Arrhythm Electrophysiol  2016,9(4),e003629","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/jce.13360","volume":"29","author":"Chugh S.S.","year":"2018","unstructured":"Chugh S.S.; Einthoven and electrical risk: Value of the electrocardiogram to predict sudden cardiac death. J Cardiovasc Electrophysiol  2018,29(1),61-63","journal-title":"J Cardiovasc Electrophysiol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1161\/HYPERTENSIONAHA.119.12684","volume":"73","author":"Verdecchia P.","year":"2019","unstructured":"Verdecchia P.; Angeli F.; Cavallini C.; Sudden cardiac death in hypertensive patients. Hypertension  2019,73(5),1071-1078","journal-title":"Hypertension"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/20961790.2019.1633761","volume":"4","author":"Cunningham K.S.","year":"2019","unstructured":"Cunningham K.S.; Spears D.A.; Care M.; Evaluation of cardiac hypertrophy in the setting of sudden cardiac death. Forensic Sci Res  2019,4(3),223-240","journal-title":"Forensic Sci Res"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/jhh.2011.104","volume":"26","author":"Cuspidi C.","year":"2012","unstructured":"Cuspidi C.; Sala C.; Negri F.; Mancia G.; Morganti A.; Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens  2012,26(6),343-349","journal-title":"J Hum Hypertens"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/clc.22957","volume":"41","author":"Li S.N.","year":"2018","unstructured":"Li S.N.; Wang L.; Dong J.Z.; Electrocardiographic left ventricular hypertrophy predicts recurrence of atrial arrhythmias after catheter ablation of paroxysmal atrial fibrillation. Clin Cardiol  2018,41(6),797-802","journal-title":"Clin Cardiol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/jch.14643","volume":"25","author":"Wang C.","year":"2023","unstructured":"Wang C.; Du Z.; Ye N.; Liu S.; Geng D.; Sun Y.; Prevalence and prognosis of atrial fibrillation in a hypertensive population: A prospective cohort study. J Clin Hypertens  2023,25(4),335-342","journal-title":"J Clin Hypertens"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"644405","DOI":"10.3389\/fcvm.2021.644405","volume":"8","author":"Liao L.Z.","year":"2021","unstructured":"Liao L.Z.; Wen X.Y.; Zhang S.Z.; Li W.D.; Zhuang X.D.; Hypertension and Atrial Fibrillation: A Study on Epidemiology and Mendelian Randomization Causality. Front Cardiovasc Med  2021,8(8),644405","journal-title":"Front Cardiovasc Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"639993","DOI":"10.3389\/fcvm.2021.639993","volume":"8","author":"Xiang H.","year":"2021","unstructured":"Xiang H.; Xue Y.; Chen Z.; The association between left ventricular hypertrophy and the occurrence and prognosis of atrial fibrillation: A meta-analysis. Front Cardiovasc Med  2021,8,639993","journal-title":"Front Cardiovasc Med"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks G.","year":"2021","unstructured":"Hindricks G.; Potpara T.; Dagres N.; 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J  2021,42(5),373-498","journal-title":"Eur Heart J"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40119-022-00260-y","volume":"11","author":"Sayin B.Y.","year":"2022","unstructured":"Sayin B.Y.; Oto A.; Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options. Cardiol Ther  2022,11(2),203-230","journal-title":"Cardiol Ther"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12872-022-02580-2","volume":"22","author":"Xu W.","year":"2022","unstructured":"Xu W.; Yang Y.; Zhu J.; Impact of renin\u2013angiotensin\u2013aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension. BMC Cardiovasc Disord  2022,22(1),141","journal-title":"BMC Cardiovasc Disord"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"e25559","DOI":"10.1097\/MD.0000000000025559","volume":"100","author":"Yu Z.","year":"2021","unstructured":"Yu Z.; Zhang D.; Ji Q.; Yi F.; Inhibition of the renin-angiotensin-aldosterone system prevents and cures atrial fibrillation. Medicine  2021,100(18),e25559","journal-title":"Medicine"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"88","DOI":"10.26574\/maedica.2020.16.1.88","volume":"16","author":"Matei L.L.","year":"2021","unstructured":"Matei L.L.; Siliste C.; Vinereanu D.; Modifiable risk factors and atrial fibrillation: the quest for a personalized approach. Maedica  2021,16(1),88-96","journal-title":"Maedica"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1136\/heartjnl-2014-307043","volume":"101","author":"Holmqvist F.","year":"2015","unstructured":"Holmqvist F.; Kim S.; Steinberg B.A.; Heart rate is associated with progression of atrial fibrillation, independent of rhythm. Heart  2015,101(11),894-899","journal-title":"Heart"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1093\/eurjpc\/zwab148","volume":"5","author":"Puig E.","year":"2022","unstructured":"Puig E.; Clar&#xE1; A.; P&#xE9;rez S.; Resting heart rate, cardiovascular events, and all-cause mortality: the REGICOR study. Eur J Prev Cardiol  2022,5(29(5)),e200-e202","journal-title":"Eur J Prev Cardiol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","volume":"34","author":"Mancia G.","year":"2013","unstructured":"Mancia G.; Fagard R.; Narkiewicz K.; 2013 ESH\/ESC guidelines for the management of arterial hypertension. Eur Heart J  2013,34(28),2159-2219","journal-title":"Eur Heart J"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"Williams B.","year":"2018","unstructured":"Williams B.; Mancia G.; Spiering W.; 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J  2018,39(33),3021-3104","journal-title":"Eur Heart J"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"17","DOI":"10.11622\/smedj.2018007","volume":"59","author":"Tay J.C.","year":"2018","unstructured":"Tay J.C.; Sule A.A.; Chew E.K.; Ministry of health clinical practice guidelines: Hypertension. Singapore Med J  2018,59(1),17-27","journal-title":"Singapore Med J"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"67","DOI":"10.11909\/j.issn.1671-5411.2019.02.001","volume":"16","author":"Hua Q.","year":"2019","unstructured":"Hua Q.; Fan L.; Li J.; 2019 Chinese guideline for the management of hypertension in the elderly. J Geriatr Cardiol  2019,16(2),67-99","journal-title":"J Geriatr Cardiol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2174\/1570161118666200518113833","volume":"19","author":"Koracevic G.","year":"2021","unstructured":"Koracevic G.; Micic S.; Stojanovic M.; Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class. Curr Vasc Pharmacol  2021,19(4),343-346","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"806743","DOI":"10.3389\/fcvm.2022.806743","volume":"9","author":"Huang T.C.","year":"2022","unstructured":"Huang T.C.; Lee P.T.; Huang M.S.; Chiu P.H.; Su P.F.; Liu P.Y.; The beneficial effects of beta blockers on the long-term prognosis of patients with premature atrial complexes. Front Cardiovasc Med  2022,9,806743","journal-title":"Front Cardiovasc Med"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"496","DOI":"10.4070\/kcj.2022.0078","volume":"52","author":"Kim D.","year":"2022","unstructured":"Kim D.; Yang P.S.; Joung B.; Optimal rhythm control strategy in patients with atrial fibrillation. Korean Circ J  2022,52(7),496-512","journal-title":"Korean Circ J"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s40256-017-0221-8","volume":"17","author":"D&#xE9;zsi C.A.","year":"2017","unstructured":"D&#xE9;zsi C.A.; Szentes V.; The real role of &#x3B2;-blockers in daily cardiovascular therapy. Am J Cardiovasc Drugs  2017,17(5),361-373","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"104274","DOI":"10.1016\/j.phrs.2019.104274","volume":"146","author":"Grandi E.","year":"2019","unstructured":"Grandi E.; Ripplinger C.M.; Antiarrhythmic mechanisms of beta blocker therapy. Pharmacol Res  2019,146,104274","journal-title":"Pharmacol Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"569","DOI":"10.12688\/f1000research.121598.1","volume":"11","author":"Ardaya R.","year":"2022","unstructured":"Ardaya R.; Pratita J.; Juliafina N.N.; Rahman F.H.F.; Leonardo K.; Amiodarone versus beta-blockers for the prevention of postoperative atrial fibrillation after cardiac surgery: An updated systematic review and meta-analysis of randomised controlled trials. F1000 Res  [version 1; peer review: awaiting peer review].2022,11,569","journal-title":"F1000 Res"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2019.03.059","volume":"286","author":"Eskerud I.","year":"2019","unstructured":"Eskerud I.; Gerdts E.; Larsen T.H.; L&#xF8;nnebakken M.T.; Left ventricular hypertrophy contributes to myocardial ischemia in non-obstructive coronary artery disease (the MicroCAD study). Int J Cardiol  2019,286,1-6","journal-title":"Int J Cardiol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3390\/life13020443","volume":"13","author":"Afr\u0103s&#xE2;nie I.","year":"2023","unstructured":"Afr\u0103s&#xE2;nie I.; Matei I.T.; Leanc\u0103 S.A.; Ischemia with nonobstructive\ncoronary artery disease and atrial cardiomyopathy\u2014two sides\nof the same story? Life  2023,13(2),443","journal-title":"Life"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ihj.2021.12.010","volume":"74","author":"Sharma Y.P.","year":"2022","unstructured":"Sharma Y.P.; Batta A.; Makkar K.; Angiographic profile and outcomes in persistent non-valvular atrial fibrillation: A study from tertiary care center in north India. Indian Heart J  2022,74(1),7-12","journal-title":"Indian Heart J"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1093\/cvr\/cvac133","volume":"118","author":"Pugliese N.R.","year":"2023","unstructured":"Pugliese N.R.; Pellicori P.; Filidei F.; Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions. Cardiovasc Res  2023,118(18),3536-3555","journal-title":"Cardiovasc Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1097\/01.hjh.0000745376.44344.37","volume":"39","author":"Petre I.","year":"2021","unstructured":"Petre I.; Diaconeasa A.; Onciul S.; Atrial fibrillation influence on left ventricular function in hypertensive patients with preserved ejection fraction. J Hypertens  2021,39(Suppl. 1),e97-e98","journal-title":"J Hypertens"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40292-022-00548-z","volume":"29","author":"Bertacchini F.","year":"2022","unstructured":"Bertacchini F.; Agabiti Rosei C.; Buso G.; Subclinical HMOD in hypertension: Left ventricular diastolic dysfunction. High Blood Press Cardiovasc Prev  2022,29(6),585-593","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jacc.2019.11.013","volume":"75","author":"Bisbal F.","year":"2020","unstructured":"Bisbal F.; Baranchuk A.; Braunwald E.; Bay&#xE9;s de Luna A.; Bay&#xE9;s-Gen&#xED;s A.; Atrial failure as a clinical entity. J Am Coll Cardiol  2020,75(2),222-232","journal-title":"J Am Coll Cardiol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.666594","volume":"116","author":"Wachtell K.","year":"2007","unstructured":"Wachtell K.; Okin P.M.; Olsen M.H.; Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: The LIFE study. Circulation  2007,116(7),700-705","journal-title":"Circulation"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"A140","DOI":"10.1016\/S0735-1097(10)61312-5","volume":"55","author":"Okin P.M.","year":"2010","unstructured":"Okin P.M.; Hille D.A.; Kjeldsen S.E.; Julius S.; Dahl&#xF6;f B.; Devereux R.B.; Sudden cardiac death in relation to changing heart rate during treatment of hypertension: The LIFE study. J Am Coll Cardiol  2010,55,A140-E311","journal-title":"J Am Coll Cardiol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/3059864","volume":"2020","author":"Yang Y.","year":"2020","unstructured":"Yang Y.; Guo S.; Huang Z.; Decreased mortality with beta-blocker therapy in HFpEF patients associated with atrial fibrillation. Cardiol Res Pract  2020,2020,1-7","journal-title":"Cardiol Res Pract"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh T.A.","year":"2021","unstructured":"McDonagh T.A.; Metra M.; Adamo M.; 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J  2021,42(36),3599-3726","journal-title":"Eur Heart J"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/heartjnl-2022-321097","volume":"109","author":"Jasinska-Piadlo A.","year":"2023","unstructured":"Jasinska-Piadlo A.; Campbell P.; Management of patients with heart failure and preserved ejection fraction. Heart  2023,109(11),874-883","journal-title":"Heart"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12916-023-02764-3","volume":"21","author":"Fauchier L.","year":"2023","unstructured":"Fauchier L.; Bisson A.; Bodin A.; Heart failure with preserved ejection fraction and atrial fibrillation: Recent advances and open questions. BMC Med  2023,21(1),54","journal-title":"BMC Med"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"748173","DOI":"10.3389\/fcvm.2021.748173","volume":"8","author":"Zhang J.","year":"2021","unstructured":"Zhang J.; Xu M.; Chen T.; Zhou Y.; Correlation between liver stiffness and diastolic function, left ventricular hypertrophy, and right cardiac function in patients with ejection fraction preserved heart failure. Front Cardiovasc Med  2021,8,748173","journal-title":"Front Cardiovasc Med"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"104369","DOI":"10.1016\/j.ebiom.2022.104369","volume":"86","author":"Schulz A.","year":"2022","unstructured":"Schulz A.; Schuster A.; Visualizing diastolic failure: Non-invasive imaging-biomarkers in patients with heart failure with preserved ejection fraction. EBioMedicine  2022,86,104369","journal-title":"EBioMedicine"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000518661","volume":"9","author":"Rismiati H.","year":"2021","unstructured":"Rismiati H.; Lee H.Y.; Hypertensive heart failure in Asia. Pulse  2021,9(3-4),47-56","journal-title":"Pulse"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1002\/ehf2.12920","volume":"7","author":"Kuo J.Y.","year":"2020","unstructured":"Kuo J.Y.; Chang S.H.; Sung K.T.; Left ventricular dysfunction in atrial fibrillation and heart failure risk. ESC Heart Fail  2020,7(6),3694-3706","journal-title":"ESC Heart Fail"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"e015343","DOI":"10.1161\/JAHA.119.015343","volume":"9","author":"Packer M.","year":"2020","unstructured":"Packer M.; Characterization, pathogenesis, and clinical implications of inflammation-related atrial myopathy as an important cause of atrial fibrillation. J Am Heart Assoc  2020,9(7),e015343","journal-title":"J Am Heart Assoc"},{"key":"ref=102","first-page":"1178","volume":"10","author":"Prasad R.","year":"2022","unstructured":"Prasad R.; Banga S.; Salazar A.M.; Correlation between atrial fibrillation and heart failure with preserved ejection fraction: A review. J Cardiol Clin Res  2022,10(1),1178","journal-title":"J Cardiol Clin Res"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2147\/CIA.S358349","volume":"17","author":"Hao C.","year":"2022","unstructured":"Hao C.; Luo J.; Liu B.; Prognostic significance of new-onset atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction following acute myocardial infarction: Data from the NOAFCAMI-SH registry. Clin Interv Aging  2022,17,479-493","journal-title":"Clin Interv Aging"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1043714","DOI":"10.3389\/fphar.2022.1043714","author":"Wo\u0142owiec \u0141.","year":"2023","unstructured":"Wo\u0142owiec \u0141.; Grze&#x15B;k G.; Osiak J.; Beta-blockers in cardiac\narrhythmias\u2013Clinical pharmacologist\u2019s point of view. Front Pharmacol  2023(3),1043714","journal-title":"Front Pharmacol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","volume":"41","author":"Brugada J.","year":"2020","unstructured":"Brugada J.; Katritsis D.G.; Arbelo E.; 2019 ESC guidelines for the management of patients with supraventricular tachycardiathe task force for the management of patients with supraventricular tachycardia of the european society of cardiology (ESC). Eur Heart J  2020,41(5),655-720","journal-title":"Eur Heart J"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"Zeppenfeld K.","year":"2022","unstructured":"Zeppenfeld K.; Tfelt-Hansen J.; de Riva M.; 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J  2022,43(40),3997-4126","journal-title":"Eur Heart J"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"200182","DOI":"10.1016\/j.ijcrp.2023.200182","volume":"17","author":"Habel N.","year":"2023","unstructured":"Habel N.; du Fay de Lavallaz J.; Infeld M.; Lower heart rates and beta-blockers are associated with new-onset atrial fibrillation. International Journal of Cardiology Cardiovascular Risk and Prevention  2023,17,200182","journal-title":"International Journal of Cardiology Cardiovascular Risk and Prevention"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1093\/eurheartj\/eht507","volume":"35","author":"Marott S.C.W.","year":"2014","unstructured":"Marott S.C.W.; Nielsen S.F.; Benn M.; Nordestgaard B.G.; Antihypertensive treatment and risk of atrial fibrillation: A nationwide study. Eur Heart J  2014,35(18),1205-1214","journal-title":"Eur Heart J"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"e005163","DOI":"10.1161\/JAHA.116.005163","volume":"6","author":"Sardana M.","year":"2017","unstructured":"Sardana M.; Syed A.A.; Hashmath Z.; Beta-blocker use is associated with impaired left atrial function in hypertension. J Am Heart Assoc  2017,6(2),e005163","journal-title":"J Am Heart Assoc"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"Maddox T.M.","year":"2021","unstructured":"Maddox T.M.; Januzzi J.L.; Allen L.A.; 2021 Update to the 2017 acc expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction. J Am Coll Cardiol  2021,77(6),772-810","journal-title":"J Am Coll Cardiol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1111\/jch.14047","volume":"22","author":"Chen J.S.","year":"2020","unstructured":"Chen J.S.; Pei Y.; Li C.; Li Y.; Wang Q.; Yu J.; Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: A network meta-analysis of randomized controlled trials. J Clin Hypertens  2020,22(12),2175-2183","journal-title":"J Clin Hypertens"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.15190\/d.2020.12","volume":"8","author":"Ahmed S.N.","year":"2020","unstructured":"Ahmed S.N.; Jhaj R.; Sadasivam B.; Joshi R.; Regression of the left ventricular hypertrophy in patients with essential hypertension on standard drug therapy. Discoveries  2020,8(3),e115","journal-title":"Discoveries"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/6628469","volume":"2021","author":"Ma H.","year":"2021","unstructured":"Ma H.; Jiang H.; Feng J.; Gan Y.; Angiotensin receptor blocker and calcium channel blocker preventing atrial fibrillation recurrence in patients with hypertension and atrial fibrillation: A meta-analysis. Cardiovasc Ther  2021,2021,1-8","journal-title":"Cardiovasc Ther"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/vhrm.2008.04.01.67","volume":"4","author":"Cuspidi C.","year":"2008","unstructured":"Cuspidi C.; Negri F.; Zanchetti A.; Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag  2008,4(1),67-73","journal-title":"Vasc Health Risk Manag"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.amjcard.2023.04.038","volume":"199","author":"Fatima K.","year":"2023","unstructured":"Fatima K.; Asad D.; Shaikh N.; A systematic review and meta-analysis on effectiveness of mineralocorticoid receptor antagonists in reducing the risk of atrial fibrillation. Am J Cardiol  2023,199,85-91","journal-title":"Am J Cardiol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1161\/HYPERTENSIONAHA.122.19020","volume":"79","author":"Mancia G.","year":"2022","unstructured":"Mancia G.; Kjeldsen S.E.; Kreutz R.; Pathak A.; Grassi G.; Esler M.; Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: Indications beyond the 2018 european society of cardiology\/european society of hypertension guidelines. Hypertension  2022,79(6),1153-1166","journal-title":"Hypertension"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/15701611113119990140","volume":"12","author":"Manolis A.J.","year":"2014","unstructured":"Manolis A.J.; Poulimenos L.E.; Kallistratos M.S.; Gavras I.; Gavras H.; Sympathetic overactivity in hypertension and cardiovascular disease. Curr Vasc Pharmacol  2014,12(1),4-15","journal-title":"Curr Vasc Pharmacol"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.phrs.2017.10.007","volume":"128","author":"Kallistratos M.S.","year":"2018","unstructured":"Kallistratos M.S.; Poulimenos L.E.; Manolis A.J.; Atrial fibrillation and arterial hypertension. Pharmacol Res  2018,128,322-326","journal-title":"Pharmacol Res"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701611264647231110101700","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/223911\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115701611264647231110101700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T17:02:43Z","timestamp":1713373363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/223911\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115701611264647231110101700","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}